FDA decisions 2023: Roche, Blueprint Medicines and GaleraTherapeuticsAugust kicked off with two FDA approvals—for Merck’s Ebola vaccine in kids and Taiho’s combination therapy for metastatic colorectal cancer—and another rejection for Mesoblast’s aGVHD treatment. Read more August 11, 2023/by BioSpace https://www.pharmalive.com/wp-content/uploads/2023/05/FDABiospace5-31-2023.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2023-08-11 08:53:442023-08-11 08:53:44FDA decisions 2023: Roche, Blueprint Medicines and Galera
